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Abstract 
 
Head and neck cancer patients often present with advanced metastatic disease resulting in a 
poor 5-year survival. Therefore, there is a need for non-invasive diagnostic tools that could 
complement conventional imaging to inform clinicians of patient outcomes and treatment 
responses. A liquid biopsy addresses this unmet clinical need; a simple peripheral blood draw 
could provide information about the disseminated disease in terms of circulating tumor cells 
and circulating tumor DNA. Moreover, detectable tumor DNA in the saliva of head and neck 
cancer patients could signify the early signs of the disease and present an opportunity for 
clinical intervention. This review provides an overview of the current literature with regard to 
the feasibility of such a test in the head and neck cancer field and highlights the need for such 
a test. 
 
Key words: Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), Head and 
Neck Cancer (HNC), Head and neck squamous cell carcinoma (HNSCC), Human 
papillomavirus (HPV) 
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 1. Introduction 
 
Head and neck cancer (HNC) is ranked the 6
th
 most common human cancer, with 
600,000 new cases resulting in 350,000 deaths annually worldwide 
1, 2
. Approximately, 90% 
of HNCs are squamous cell carcinoma (HNSCC) and commonly originate from the mucosal 
lining of the epithelium 
3, 4
.  HNCs include tumours originating from the lip, oral cavity 
(mouth), nasal cavity (inside the nose), paranasal sinuses, pharynx, and larynx. As such, these 
tumours cannot be grouped together because of the distinct biological and clinical features 
due to the anatomical site of origin. As an example, nasopharyngeal cancers are 
predominantly caused by Epstein Bar Virus and oropharyngeal cancers are as a result of 
Human Papillomavirus (HPV-16 and HPV-18 oncogenic types) infections.  
The high mortality rate in HNCs is primarily due to late diagnosis and metastasis 
(combined locoregional and distant) resulting in a 5 year survival rate of less than 50% 
3, 5
. 
The dissemination of the cancer tends to more locoregional (50-60%), of which (15-25%) of 
patients progress to distant disease 
3, 6
. Early stage (I and II) HNSCC patients are generally 
treated with a single modality, however for more advanced stage patients (III-IV), combined 
modality treatment is utilised. The treatment options are surgery, chemotherapy and 
radiotherapy 
7
. However, current interventions expose patients to high levels of toxicity albeit 
with relatively poor efficacy at targeting local and distant spread 
8, 9
. In patients with locally 
advanced disease, there is no optimal treatment and many patients will relapse with distant 
disease 
7, 10
. Combining chemotherapy with surgery and radiation has improved survival; 
however treatment failure is observed in more than 50% of cases in stage III-IV tumours 
11
.  
 
The risk factors for developing HNCs are tobacco and alcohol consumption, betel nut 
chewing, dental trauma, and infection with HPV-16 and HPV-18 pathogenic variants 
12-14
. 
Globally, HPV-16 prevalence within the oral cavity is highest in China (81%) and India 
(74%), followed by the Netherlands (63%), Spain (47%), United Kingdom (20%) and United 
States (20%)
15
 . HNSCC is often preventable if diagnosed early 
5
, however, patients often 
present with advanced stages of the disease, which requires aggressive treatment and can 
leave the patient with disfigurements and a poor quality of life 
5, 16
. For HNCs, distant 
metastases tends to occur in the lungs (66%), bone (22%), liver (10%), skin (>2%), 
mediastinum (>2%), bone marrow (>2%) respectively and the dissemination of the tumour 
cells to distant sites is typically associated with further functional loss and increased mortality 
17-19
. 
 
Various forms of endoscopy and tumour biopsy are the current standard methods in 
diagnosing HNCs. In areas that are difficult to access, ultrasound guided fine-needle aspirates 
(FNA) can be used to sample the site 
20, 21
. These techniques allow a pathologist to confirm a 
cytological or histological diagnosis and inform the treating clinician. The down-side to this 
approach is that only a single sample is used to diagnose the disease not taking into 
consideration tumour heterogeneity, multiple biopsies can be  expensive and in some cases, 
leave the patients disfigured or facing unnecessary risks 
8,22-25
. To overcome these hurdles, a 
simple peripheral blood draw informing clinicians of the patients’ tumour burden is desirable. 
A ‘liquid biopsy’ presents an option where the disease can be tracked in a less-invasive, 
simple manner, allowing for serial sampling informing of the tumour heterogeneity, response 
to treatment and minimal residual disease  
5, 22, 26
. 
D
ow
nl
oa
de
d 
by
 [Q
ue
en
sla
nd
 U
niv
ers
ity
 of
 T
ec
hn
olo
gy
] a
t 2
0:1
5 0
3 D
ec
em
be
r 2
01
5 
A liquid biopsy represents a promising tool to track tumour-specific changes during 
the course of the disease. A liquid biopsy can be used to identify potential indicators for 
disease recurrence as well as disease progression and may indicate if a specific treatment is 
effective or will reduce the risk of recurrence 
26
. For example, in some cancer types, the 
presence of circulating tumour DNA (ctDNA) in patients after curative treatment indicates 
the presence of residual disease and is likely to be a prognostic marker of relapse 
27, 28
. With 
the use of a liquid biopsy throughout the course of treatment, we can determine the 
effectiveness of treatment versus likely recurrence, as well as observe the presence of 
minimal residual disease 
28-31
.  
 
1.1 Liquid biopsies: a comparison of circulating tumour cells to circulating cell-free 
nucleic acids 
Circulating tumour cells (CTCs) are rare, metastatic precursor cells, found within the 
lymphovasculature, released into circulation by primary or metastatic tumours. In recent 
years, detection of CTCs in breast, prostate, colorectal and lung cancers have shown 
correlations with tumour staging, and advanced disease with CTC counts higher than certain 
levels correlating with poor patient prognosis and outcomes 
22
. The prognostic value of CTCs 
in HNCs is currently under investigation, with the clinical utility yet to be established. 
Studies in CTCs across multiple tumour types have revealed that the tumour cells in 
circulation have a short half-life and only a fraction survive to metastasize due to the harsh 
conditions found in blood (shear forces, immunologic and apoptotic processes and fluid 
turbulences) 
13
,   Studies have shown that CTC status varies with nodal spread and disease 
stage in HNCs using  Immunomagnetic separation (CellSearch®), Microfluidic platforms 
(Chip), and cellular-marker based enrichment (EpCAM, CD45) 
4, 13, 32-33
. There has been a 
shift in enrichment technologies from a marker based selection (EpCAM) to non-biased, 
more inclusive, ‘label-free’ technologies which are able to capture a greater CTC population 
34
. Currently, microfluidics platforms are taking centre stage in isolation and numerations of 
CTCs 
35-38
. Moreover, in recent years, CTC cultures have come to the fore as advancements 
in CTC isolation and enrichment technologies have evolved 
39
. Culturing CTCs ex vivo adds 
a new dimension as it allows for the creation of CTC cell lines and drug sensitivity tests as a 
means to advancing personalised medicine. In addition, patient derived CTCs and organoid 
cultures allow for recapitulation of the molecular diversity present within the tumour and 
disseminated disease and this may provide a better model for understanding disease 
progression as well as testing response to treatment and treatment resistance 
40
. Moreover, in 
small-cell lung cancer, CTCs isolated from patients were shown to be tumorigenic in 
immune-deficient mice and the resultant CTC derived explants mirrored the donor patient’s 
response to 2 chemotherapeutics 
41
.  There is no literature relating to CTC derived explant 
work in head and neck cancers. 
Circulating DNA fragments carrying tumour-specific sequence alterations; 
Circulating Tumour DNA (ctDNA), is found in the cell-free fraction of blood, representing a 
variable and small fraction of the total circulating DNA
42
. ctDNA is thought to carry somatic 
mutations which have arisen in primary and/or secondary tumours, and thereby holds 
potential as a biomarker within the cell-free fragment of blood. ctDNA is thought to originate 
from tumour deposits and lysed CTCs in circulation 
22
, and being a cell-free marker, it is 
much easier to sample than intact whole CTCs 
22, 29
. Moreover, ctDNA offers the same 
diagnostic advantage in real-time monitoring of response to therapy, disease prognosis and 
emergence of treatment resistance 
43
. ctDNA is reported to be a highly sensitive biomarker of 
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metastatic disease, directly reflecting tumour burden and dynamics in pancreatic, lung, 
colorectal, breast and prostate cancers 
27, 29, 42, 44-46
. 
Current utility of CTCs and ctDNA is based on the assumption that they share 
common somatic mutations and genomic rearrangements as the primary/secondary tumours. 
This implies that we can obtain a true signature of the tumours with respect to mutational 
status without the need for an invasive tissue biopsy. Current studies have used CTCs and/or 
ctDNA to validate this concept 
42, 44
. With this in mind, we present the idea that CTCs and 
ctDNA can be used in combination to determine the clinical efficacy of metastatic status in 
HNC (Figure 1). As both CTCs and ctDNA technologies evolve, they will likely have similar 
as well as distinct clinical applications 
22
. However, both are integral as real-time approaches 
with therapeutic success depending upon effective integration between real-time diagnostics 
and targeted interventions. The focus of this review is to assess the literature on CTCs and 
ctDNA in their clinical utility for detecting HNC events. 
 
1.2 The Use of Circulating Tumour DNA in Head and Neck Cancers 
ctDNA studies for HNCs trails behind other mainstream cancers such as breast, 
ovarian, prostate, colorectal and lung. In a study in which 640 cancer patients across multiple 
tumour types, 10 were HNSCC patients (tumour stage IV). Approximately 70% were found 
to have detectable ctDNA mutant fragments within their plasma. The gene mutations for 
HNSCC identified were PIK3CA (30%), TP53 (50%), BRAF (10%) and AKAP9 (10%) 
44
. 
These findings are consistent with The Cancer Genome Atlas (TCGA) data, which had found 
TP53 (72%), PIK3CA (21%), FAT1 (23%) and CDK2NA (22%) as key mutations in HNSCC 
tumours 
47
. In the study of Bettegowda et al., only late stage (IV) patients were included 
rather than early stage patients (I-II) signifying an advanced stage HNC patient cohort with a 
higher burden of disease and relatively higher tumour derivatives in circulation 
22, 27, 43
. 
Interestingly, in the same study, ctDNA was readily detectable in breast, colorectal and 
ovarian cancers with > 80% specificity in late stage patients (III, IV). Moreover, ctDNA has 
shown to be detectable in other tumour types in stage I (47%), II (55%), III (69%) and IV 
(82%) 
44
. Their findings also detected CTCs and ctDNA in the same samples, however CTCs 
were not always found when ctDNA was detectable.  This could be due to the unavailability 
of high signal to noise ratio technologies. 
In a second study to evaluate ctDNA in HNC, ctDNA mutations were screened 
against tumour tissue, to observe mutational consistency between ctDNA, primary and 
secondary tumours. In this study, 3 HNSCC patients were recruited and biopsies of the Skin, 
Lymph nodes, and Nasal cavity were collected and sequenced. Patients then underwent 
curative, Methotrexate and Paclitaxel treatments. Post-treatment plasma samples were 
collected to test for ctDNA. The results suggested that there is a concordance between biopsy 
and plasma samples as the mutations found in ctDNA were also present within the tumour 
27
. 
These findings were also found in a multitude of cancer types including Breast, Colorectal, 
Ovarian, and Lung carcinomas. Overall, Lebofsky et al. concluded 97% detection 
concordance between tumour mutations identified from biopsies and ctDNA 
27
. From the 3 
HNSCC patients sampled in Lebofsky et al. study; those with a greater number of metastatic 
lesions had a greater concentration of ctDNA. This again, contributes to the school of thought 
that, a large tumour burden results in higher concentrations of ctDNA, due to greater cellular 
turnover 
27, 43, 48
.  Lebofsky et al. also highlights the 3% discordance between tumour biopsy 
and ctDNA samples as a result of the heterogenic nature of the cancer. It has been 
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hypothesised from this that quantitative ctDNA detection may reduce the heterogeneity-
related bias over single-site biopsies, as more than one metastatic site is likely to be shedding 
its genetic material. This study also demonstrated the significance for ctDNA as a potential 
biomarker for primary and metastatic tumours, as the mutational variation is minimal 
between solid tumour and ctDNA. ctDNA sampling minimises heterogenetic bias, and its 
presence can be detected in earlier stages, which was previously unconfirmed in Bettegowda 
et al., study. 
 
More recent studies have shown proof-of-principle for ctDNA as a biomarker in 
HNSCCs, with both blood and saliva serving as a diagnostic medium. In a cohort of 93 
HNSCC patients, plasma or saliva samples were collected to identify somatic mutations 
(TP53, PIK3CA, CDKN2A, HRAS, NRAS) and HPV (HPV-16,-18). Tumour DNA was 
detected in 76% of saliva samples (n=93) and 87% of plasma samples (n=47) respectively, 
with TP53 as the most common mutant detected (86%). Those patients with oral cavity 
cancers were all shown to have tumour-specific DNA in their saliva samples (100%, n=46). 
Due to known aetiological factors between HPV and HNSCCs, patients were screened and 
clustered as either HPV positive or negative. HPV negative patients were predominantly 
TP53 mutant (92%, n=26), while 86% (n=18) of HPV-positive patients had detectable HPV 
DNA in either plasma and/or saliva 
49
. Furthermore, patients presenting with early and 
advanced stage disease were also screened for ctDNA; results showed 100% detection in 
early and 86% in advanced patients 
49
. Saliva was shown to be a more sensitive predictor than 
plasma for early stage disease, with 100% detection in saliva versus 70% in plasma. Whereas 
in Late stage disease patients (stage III and IV), plasma was the preferred medium with 92% 
tumour-specific DNA detection, versus 70% detection in saliva 
49
. This difference in 
sensitivity is attributed to the site of the cancer
49
. For example, Wang et al.,’s detection in 
saliva varied from site to site; 47% (oropharyngeal), 70% (laryngeal) and 67% 
(hypopharyngeal). In this case, these sites were not directly sampled by oral rinse samples.  
The same sites showed better detection, (91%, 86% and 100%) from sampled plasma. It is 
thought that oral specific tumour DNA is more readily detected in the oral cavity due to the 
close proximity to saliva and the tumour, with DNA shedding into localised area.  Whereas in 
occult primary and secondary tumours, as well as advanced stage patients, tumour DNA is 
likely to be found in plasma due to systemic dissemination and locally advanced tumours 
shedding into circulation, as opposed to the one anatomical site 
27, 44, 49
. It can be inferred 
from this study that saliva is a better diagnostic fluid in the detection of mutations specific for 
HNSCCs as it’s been shown to be more sensitive in gene mutation and HPV DNA detection; 
however, there are several limitations to using only saliva for HNSCC mutant detection. 
Saliva is not always present or easily collected from the oropharynx, hypopharynx, larynx 
and other structures deep within the oral cavity and hence DNA that is shed may not be non-
invasively sampled through this route. Oral rinses may allow for deep pharyngeal sampling, 
but, not only has it been shown to be less effective, it may be difficult for the patient to 
provide such samples. Alternatively, mutant fragments were shown to be 10 times more 
prevalent in plasma than in saliva 
49
. Hence, for effective screening of patients in HNC, it 
seems optimal that a combined saliva and plasma analysis be utilised to ensure that mutations 
found are concordant and discern HPV integration. This ensures that all measures are being 
taken to screen for mutations, and removes any heterogenetic or anatomical bias introduced 
from one sample from one locality. 
 
1.3 ctDNA and its association with Human papillomavirus status  
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Currently, HPV status is used as a predictive marker for overall survival in 
oropharyngeal squamous cell carcinoma (OPSCC) , with HPV-positive status linked to better 
overall outcomes than HPV-negative patients 
14, 50
. Studies have shown that HPV viral 
integration can be detected in circulation using HPV-16/18 gDNA as a molecular marker (C-
HPV DNA), with 85% of cervical neoplasia patients found positive for c-HPV DNA in 
serum
51
. C-HPV DNA was also found in the absence of ctDNA in 2 patients, suggesting that 
circulating viral DNA may have diagnostic potential in the absence of ctDNA 
51
. In this 
regard, ctDNA may help to assess disease prognosis and tumour sensitivity to HNC therapies.  
 
2. Circulating Tumour DNA detection technologies 
The detection of ctDNA refers to the observation of mutant DNA fragments amongst 
the wild-type fragments free in circulation. Current genomic technology advances have 
initiated a paradigm shift towards high-throughput, high sensitivity, dynamic platforms. This 
new technology has been slow to adopt over more traditional methods, due to cost and 
logistical faults.  As stated previously, it’s been shown that ctDNA is detectable in the plasma 
and saliva of early stage patients in HNC 
49
, hence ctDNA detection at the pre-cancerous 
stage could allow for early intervention and possible cure, before the onset of advanced or 
disseminated disease. For late-presenting patients where curative treatment is less effective, 
the quantity of ctDNA has shown to be correlative to treatment response, which provides an 
avenue for better disease monitoring 
29, 48
. 
Advanced HNSCC patients (Stage III, IV) vary in mutant-to-wild-type allele fractions in 
circulation (from 0.016-2.858% in plasma samples) and for earlier patients (Stage I, II) these 
allele fractions are typically less; this is thought to be dependent on the tumour locality and 
sample collection 
22, 48, 49
. Current technologies focus on the detection of ctDNA in 
comparison to wild-type allelic frequency; in order to use these tumour-specific genetic 
markers, the mutations must be easily differentiated from an excess of non-mutant DNA. We 
will now focus on the developing molecular systems which have the potential to screen and 
analyse these rare- genetic events. 
 
2.1 Digital Droplet PCR (ddPCR) 
Digital droplet PCR (ddPCR) enables quantification of nucleic acids. The digital 
droplet system generates hundreds of thousands of droplets from an initial PCR mix, with 
each droplet representing an isolated PCR endpoint reaction. Collected DNA is 
compartmentalised into droplets with probes specific for mutation and wild-type alleles, each 
probe conjugated to fluorescent tags. Thereby, positive and negative mutations can be 
quantified based on the frequency of fluorescence. 
 
Several studies have evaluated the efficacy of ddPCR platform on mutant allele detection in 
comparison to known standards of DNA quantification. In one study to evaluate EGFR 
mutation, it was shown that ddPCR outperformed the current gold standard of amplicon 
quantification, qPCR, showing detection of up to 0.1% mutant fraction 
52
. Recent studies 
have also shown the sensitivity and specificity of ddPCR in detecting KRAS mutations. Using 
ddPCR, it was possible to detect 1 KRAS gene in a background of 200,000 wild-type genes 
53
, 
which is a sufficient limit of detection for early stage tumour DNA in plasma 
45
. Others have 
confirmed ddPCR as an effective platform for EGFR mutation detection in Lung cancer, with 
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their limit of detection as low as 0.02% mutant alleles, with interfering background 
amplification at 0.03%. Their study shows ddPCR outperforming qPCR in both robustness of 
detection as well the dynamic range, with ddPCR detection at 100% and qPCR at 96%, in 
concordance with known EGFR mutants present from biopsy (n= 35) 
54
. ddPCR is 
advantageous as a mutation detection platform because it excludes the need for a standard 
curve, it has a greater dynamic range and it allows for absolute quantification, directly 
measuring the  number of DNA molecules for more direct quantification of mutant-to-wild 
type frequency 
54
. ddPCR reaction partitioning also allows for less sample and reagents 
needed for mutational analysis. 
 
 
2.2 QanTAS (Quantitative Threefold Allele Specific PCR) 
 
 More recently, technology which favours high sensitivity and is applicable to detect 
and amplify minimal residual disease analysis has been coined as QanTAS-PCR. It is an 
allele-specific PCR assay (ARMS), which minimises background wild-type amplification and 
distinguishes true from false positive results, in order to accurately detect the presence of rare 
genetic aberrations 
30
. Zapparoli et al.’s assay interrogates specifically JAK2 V617F alleles 
that are implicated in myeloproliferative neoplasms. From the assay, they confirmed 1-3 
mutant alleles identified per 10,000 JAK2 wild-type copies per well. Their 3 stage combined 
approach with Cq value false-positive identification, effectively distinguished the number of 
true and false positives present within the assay. As such, QanTAS-PCR boasts its sensitivity 
as 0.0001% per replicate, which is comparative to new Digital PCR sensitivities 
30
. 
 
 
2.3 Modified FAST SeqS  
 
Modified FAST-SeqS is an assay which relies on patient ctDNA concentration, and 
relative copy number variation (CNV) to monitor the incidence of minimal residual disease 
and estimate ctDNA percentages within the total cfDNA. Analysis of tumour genomes is 
better facilitated if high amounts of ctDNA are present, and by using mFAST-SeqS it is 
possible to pre-screen applicable patients for untargeted whole-genome sequencing. mFAST-
SeqS is applicable in HNSCC, as it’s utility minimises some of the inherent problems in 
treatment decision making; for example, we can better identify multiple driver mutations and  
monitor patients with evolving advanced or recurrent disease, without the need for multiple 
site sampling and invasive biopsy required for whole-genome sequencing. Current ctDNA 
analysis relies on multiple targets to obtain a detailed characterisation of the tumour and often 
require primary tumour tissue for a suitable repertoire of genes. This is why untargeted 
approaches are more favourable in some clinical scenarios. 
There are several inherent problems with this untargeted approach, however, namely the 
minimum fraction of ctDNA required for reliable detection using mFAST-SeqS, and the 
variation between CNV’s and ctDNA concentration 55 Belic et al., assay relies heavily on 
ctDNA concentrations ≥ 10% for untargeted whole-genome sequencing. It has been shown 
previously that ctDNA fractions in HNSCC are highly variable even in patients with 
advanced and disseminated disease 
44, 49
. While an untargeted approach is useful in 
identifying patterns of CNVs and monitoring the evolution of the tumour genome, ctDNA 
fractions aren’t always 10% of the total circulating DNA, so not all patients are applicable for 
analysis. Other limitations include the fraction of identified mutant alleles versus the fraction 
of ctDNA. Patients may have high fractions of ctDNA, but if CNA is low, then the threshold 
of detection is limited. 
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 3.  Expert commentary and five-year view 
 
Recent published studies have explored the diagnostic potential of ctDNA, focusing 
on advanced stage patients across multiple tumour types, with variable patient cohorts and 
small HNC sample cohorts. Heterogeneous HNSCC cancer types, CTCs counts versus 
ctDNA mutant-to-wild-type ratio, limit of detection and sample site collection are all 
variables which need to be taken into consideration prior to clinical implementation of 
ctDNA. Moreover, ctDNA as a genetic biomarker in HNSCC must overcome these issues 
with larger studies and consistent streamlined methods for early, advanced and late stage 
detection, as well as specific assays and technologies which confirm or nullify those 
mutations which are implicated in HNSCC oncogenesis. The clinical utility of CTCs in HNC 
is currently under investigation by a number of groups around the world. Advancements in 
enrichment technologies from a marker-based bias to label-free platforms and ex vivo culture 
of CTCs coming to the fore. This opens up the utilisation of CTCs in HNCs, which are 
known to have low numbers of CTCs.  
 
As next-generation sequencing and other quantitative gene expression platforms 
become cost-effective, more sensitive and specific in detection of rare fractions of mutant 
DNA amongst wild-type background amplification; then the detection of minimal residual 
disease may hold prognostic significance. Furthermore, head and neck cancer derived 
vesicles (exosomes and macrovesicles) have been enriched in tumour antigens and cargo, 
which could be an alternative biomarker source 
56
.   The current clinical implications of 
sample collection via plasma or saliva in HNSCC are up for debate and may be variable 
depending on a variety of patient factors including tumour location, stage of disease, 
metastatic and recurrent disease states. Furthermore, the significance of using CTCs, ctDNA 
or a combined modality to complement current imaging platforms (CT/MRI scans) may aid 
in the management of HNSCC patients, however at this stage, further studies are required to 
determine the efficacy of each approach individually as well as combined, in order to 
optimise treatment and determine whether this improves overall survival. With extensive 
investigation and characterisation of CTCs and ctDNA comparatively, we can ultimately 
determine the clinical utility of a liquid biopsy in HNSCC.  
 
Key issues 
 
 Head and neck cancers account for the 6th most common cancer globally 
 Early detection of head and neck cancer events allows for clinical 
interventions leading to better clinical outcomes and overall survival 
 Non-invasive biopsies through mediums such as saliva and peripheral blood 
are preferred to invasive tissue biopsies 
 Circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) are 
biomolecules which can be non-invasively sampled from head and neck 
cancer patients 
 CTCs can inform of patients at risk of developing metastasis before 
clinically/radiographically detectable metastasis form 
 ctDNA can be detected in early stage patients in saliva and in the plasma of 
more advanced stage head and neck cancer patients 
 CTCs and ctDNA as biomarkers, have the potential to complement 
conventional imaging platforms in head and neck cancer patients. 
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 Clinically, CTC detection allows for determining patients at-risk of developing 
metastasis whereas ctDNA allows for determining minimal residual disease 
Acknowledgements 
 
We thank Professor William B. Coman (School of Medicine, University of Queensland, 
Queensland, Australia) for his clinical input in this review and Dr Sarah-Jane Dawson 
(Molecular Biomarkers and Translational Genomics Laboratory and Department of Medical 
Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia) for editorial 
assistance. 
 
Financial & competing interests disclosure 
This study was supported by the Queensland Centre for Head and Neck Cancer funded by Atlantic 
Philanthropies, the Queensland Government, and the Princess Alexandra Hospital. The authors have no other 
relevant affiliations or financial involvement with any organization or entity with a financial interest in or 
financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.  
 
 
Figure 1. A schematic representation of the use of liquid biopsy for metastatic head and 
neck cancers. 
 
 
Circulating tumour DNA (ctDNA) in the saliva and blood of a patient as well as circulating 
tumour cells (CTCs) in the lymphovasculature (single, doublets and clusters) which are able 
to metastasize to distant sites (lungs, liver, bone).   
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